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Available online 2 December 2013AbstractCrohn’s disease in combination with ulcerative colitis is one of the two most recognized inflammatory bowel colitides. First presentation at
the onset of Crohn’s disease varies widely among individuals, with toxic colitis and megacolon being the most severe and often most
remembered presentation. Medical registrars and acute physicians alike are faced with making decisions about admission and discharge of
patients with acute abdominal pain, and awareness of the diversity of Crohn’s disease pathology is of paramount importance in order not to
discharge patients prematurely. This article discusses the six most common presentations of Crohn’s disease to the Acute Medical Unit and
informs about optimal management.
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Crohn’s disease (CD) is a type of inflammatory bowel
disease (IBD) that may affect any part of the gastrointestinal
(GI) tract, from the mouth to the anus, but commonly affects
the terminal ileum. It is characterized by transmural inflam-
mation with mucosal hyperemia with superficial ulcers in mild
forms of the disease ranging to deep serpiginous ulcers, known
as the characteristic “cobblestone” appearance, in moderate to
severe forms.1 In addition to weight loss, patient often
complain of chronic diarrhea and right iliac fossa pain. To
date, what causes CD is not clearly defined, but interactions
between environmental, immunological, and bacterial factors
seem to play an important role in genetically susceptible pa-
tients. Pathogens that have been postulated include Myco-
bacterium avium paratuberculosis, Helicobacter species, or
adherent invasive Escherichia coli.2 Males and females are
equally affected. Smokers are twice as likely to develop CD as* Royal Preston Hospital, Department of Anaesthesia and Intensive Care,
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http://dx.doi.org/10.1016/j.jacme.2013.10.001nonsmokers.3 The incidence is higher in industrialized coun-
tries, urban areas, and upper socioeconomic classes with
prevalence estimates in Northern Europe ranging from 27 to
48 per 100,000.1,4
To date, there is extensive research into the field of factors
predicting disease flare-ups and progression; however, there is
no clear consensus as yet. In general, patients appear more
likely to develop disabling or complicated CD when several
factors are present, such as young age at onset (pediatric or
<40 years), small bowel disease, structuring, deep ulcers at
endoscopy, perianal disease, weight loss of >5 kg, steroid
need for the first flare-up at diagnosis, or need for early
immunosupression and/or biological therapy.5,6
The majority of patients with CD have mild to moderate
disease and are nowadays primarily managed in multi-
professional gastroenterology outpatient clinics, involving
gastroenterologists and specialist nurses. However, patients
may experience severe flare-ups or present to the Acute
Medical Unit (AMU) with their first ever episode of CD.
Possible acute presentations include acute severe colitis and
toxic megacolon, intestinal hemorrhage, intestinal obstruc-
tion and perforation, abscess formation and complications ofMedicine. Published by Elsevier Taiwan LLC. All rights reserved.
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boembolism (VTE), and perhaps less commonly acute in-
testinal failure. Prompt assessment and initiation of care can
reduce morbidity and mortality in these patients and aid
appropriate referral to other specialties, such as gastroenter-
ology or general surgery, or result in rapid discharge. This
review aims at providing an overview of the most common
acute presentations of CD and how to recognize and manage
them effectively on the AMU.
2. Toxic colitis and toxic megacolon
Among all IBD emergencies, toxic colitis with or without
megacolon is inadvertently the most life-threatening compli-
cation.7 In up to 30% of patients, it may occur as the initial
presentation of disease,8 or if not at the onset, it may occur at
any time during its course. Although the general belief is that
acute severe colitis or toxic megacolon is rare in CD and mainly
affects patients with ulcerative colitis, studies have shown that
CD is the etiology in approximately 50% of cases.9 One series
of 1236 patients admitted to hospitals over a 19-year period
showed that toxic megacolon was present in 6% of patients,
specifically 2.3% of CD admissions.10 In fact, toxic colitis may
complicate any number of colitides, including inflammatory,
ischemic, infectious, radiation, and pseudomembranous.11
Patients with acute severe colitis commonly present with
abrupt onset bloody diarrhea and rectal bleeding, abdominal
pain or tenderness, anorexia, vomiting, and fever. A patient is
considered to be “toxic” if, in addition to severe colitis, they
fulfill the Jalan et al12 diagnostic criteria: radiographic evi-
dence of total or segmental colonic dilatation (classic finding
is >6 cm in the transverse colon); three of the followingdf-
ever (>38.6C), tachycardia (>100 beats/minute), leukocy-
tosis (>10.5  103/mL), or anemia; and one of the
followingddehydration, altered mental status, electrolyte ab-
normality, or hypotension.
The histopathological features of toxic colitis are similar in
CD and ulcerative colitis. Inflammation extends beyond the
mucosa into the smooth-muscle layers and serosa, ultimately
involving all layers of the colon. This is associated with
transmural vascular congestion, deep ulceration, and muscle
disintegration. Even though these features are well described,
the etiology of toxic colitis and megacolon are yet to be un-
veiled. Potential explanations include paralysis of the smooth
muscle by inflammatory infiltrate, destruction of the myenteric
plexus or the Auerbach’s plexus,13 or elevated levels of nitric
oxide and nitric oxide synthase activity.14 Ultimately, the
colon becomes atonic, dilated, and inactive.
Assessing patients as part of the acute take means that acute
physicians and medical registrars as much as more junior
doctors need to be aware of factors that can trigger or further
the development of toxic megacolon. Agents to be avoided in
particular include narcotics, antidepressants, opiod analgesia,
anticholinergics, anti-inflammatory medication (nonsteroidal
anti-inflammatory drugs), and antidiarrheal medication, such
as loperamide. The rapid tapering or abrupt discontinuation of
medications, such as steroids, sulfasalazine, and 5-aminosalicylic acid, is also discouraged as it may precipitate
dilation. Counterproductive events also include barium enema,
colonoscopy, or concomitant hypokalaemia.9
The workup of a patient with toxic colitis should include a
full blood count, a full biochemistry panel (renal/liver/bone),
coagulation studies (international normalised ratio, INR), and
C-reactive protein (CRP). Potential findings can include a
leukocytosis with a left shift, anemia, electrolyte imbalances
such as hyponatraemia and hypokalaemia, hypoalbuminemia,
and elevated inflammatory markers; however, it is worthwhile
to remember that these findings are nonspecific. One of the
most crucial steps is the exclusion of GI infection. A sub-
stantial number of pathogens can precipitate bloody diarrhea,
such as Clostridium difficile, Shigella, Salmonella, enter-
oinvasive, and enterohemorrhagic E. coli, or viruses such as
cytomegalovirus, to name but a few.7
In order to make the diagnosis, the clinician needs to re-
view the plain abdominal radiograph. Patients with toxic
megacolon will have one or several of the following features:
dilated transverse colon (>6 cm), loss of colonic haustrations,
presence of intraluminal soft tissue masses (pseudopolyps), or
free intraperitoneal air. Ultrasonography15 or abdominal
computed tomography (CT) scan16 can help to visualize the
colon, if the diagnosis remains uncertain. Following expert
advice, a flexible sigmoidoscopy may also be undertaken. A
colonoscopy should not be attempted in view of the serious
risk of perforation, both by bowel preparation and the pro-
cedure. The advantage of flexible sigmoidoscopy is the sam-
pling of inflammed mucosa for histopathology. This often
allows the colitis to be classified into ulcerative or Crohn’s
colitis.7
Once the diagnosis of toxic colitis is suspected, patients
require admission and prompt and aggressive medical treat-
ment on the AMU.17 This includes adequate fluid and elec-
trolyte resuscitation in combination with intravenous
high-dose steroids (100 mg hydrocortisone every 6 hours for
5 days) and broad-spectrum antibiotics. Several series have
suggested that colectomy can be avoided in 40e73% of cases
when steroids are administered promptly. To date, there have
been no randomized controlled trials evaluating the use of high
dose steroids because of ethical issues, but high dose steroids
have been widely adapted as the gold standard therapy to
induce remission.7 Plain abdominal radiographs should also be
repeated regularly to quantify dilation of the colon. The fre-
quency depends on the clinical state of the patient and can
range from twice daily to every other day.17
As the acute physician on AMU, it is most important to co-
ordinate themultidisciplinary team,with involvement fromboth
gastroenterologists and general surgeons. Surgical involvement
early on is key to offer prompt intervention when indicated, for
example, if the toxic megacolon is unresponsive to steroid
therapy after 5e7 days, or there is evidence of perforation,
peritonitis, or massive hemorrhage. If surgical input is delayed,
mortality secondary to toxic megacolon has been shown to in-
crease: if surgical input is delayed to the point of CDperforation,
mortality may be >40%, whereas if surgery is completed prior
to the perforation themortality is between 2%and 8%.7,14 So far,
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of medical therapy upon admission. It is therefore of paramount
importance that acute physicians remain vigilant, especially
when considering that patients with toxic colitis or megacolon
are admitted to hospitals via the AMU and may remain on the
AMU for several days prior towhen a side room or bed becomes
available on a gastroenterology ward.
3. Intestinal hemorrhage
Unlike ulcerative colitis, where bleeding is often profuse
because of pancolitis, bleeding in CD is often from a localized
source caused by erosion of blood vessels within multiple deep
ulcerations that extend into the bowel wall. Because CD can
affect any part of the GI tract, from the mouth to the anus, it is
often difficult to predict the source of the bleeding: Homan
et al,18 for example, found the small bowel to be the source of
the bleeding in 65% of the patients, but was unable to locate
the source in 23%. Cirocco et al19 localized the bleeding to the
terminal ileum in 66% of the patients, a finding that was later
also supported by Karoui et al.20 In general, severe bleeding in
CD is most commonly seen in patients with active ileal
disease.21
The initial management of CD hemorrhage is resuscitation
and stabilization of the patient. This may involve several
units of blood or replacement of clotting factors. Following
this, the source of the bleeding needs to be established.
Various investigations are available to the physician. In
addition to classical diagnostic methods, such as colonos-
copy/sigmoidoscopy, gastroduodenoscopy, angiography, or
radionucleotide scanning, several new methods have emerged
recently, for example, capsule endoscopy, angiography in
combination with methylene blue, and angio-CT.22 The acute
physician will need to consider the clinical setting, and
availability of and access to investigations when requesting
for this information on AMU. Not all of the investigations are
readily available or applicable when considering the clinical
scenario, and the opinion of a gastroenterologist may be
sought first.
The initial approach in all patients is conservative, and only
if bleeding recurs or fails to settle on conservative manage-
ment, is surgery indicated.22,23 Again, early involvement of the
surgical team is key to success, as the surgical approach needs
careful planning: if the bleeding, for example, originates from
an area of the small bowel, resection and primary anastomosis
can be undertaken. In case of bleeding due to Crohn’s colitis,
an abdominal colectomy may be indicated and ileorectal
anastomosis is only an option if the rectum is free of disease.9
4. Intestinal obstruction and acute perforation
Intestinal obstruction is common to both ulcerative colitis
and CD, but is more common in the latter. Small bowel
obstruction is the most common presentation, requiring surgical
input and may affect 35e54% of patients.24 Because of the
nature of CD, obstruction can occur in several clinical scenarios,
such as secondary to acute active inflammation superimposed ona stenotic portion of the bowel, fibrosis and scarring with
stricture formation, or mass effect from a phlegmon or abscess.9
The most common location for small bowel obstruction is the
terminal ileum. Symptoms include (severe) cramp-like
abdominal pain, bloating, distension, nausea and vomiting,
and constipation with a reduction in or absence of flatus. Once
the obstruction settles, patients often experience explosive
diarrhea due to rapid passage of the intestinal content.
Management is medical at first instance, and once an ab-
scess has been ruled out, this usually involves bowel rest,
intravenous fluids, placement of a nasogastric tube for
decompression, and 5-ASA compounds and steroids. The
majority of obstructions attributed to an acute active flare-up
will resolve as inflammation and edema settle, usually
within 2e3 days. Only those that fail to respond will require
emergency surgical intervention. Often, it is difficult to
distinguish whether small bowel obstruction is due to
inflammation or fibrostenosis, so a trial of steroid therapy is
often advocated. Obstruction due to fibrostenosis is less likely
to resolve spontaneously and ultimately requires surgical
resection. Whenever a stricture is found to be the underlying
pathology, it is vital to consider a diagnosis of malignancy:
Yamazaki et al25 noted a 6.8% malignancy rate in 132 patients
with colonic CD complicated by stricture. Nonsurgical treat-
ment for CD-related strictures also includes enteroscopic
balloon dilation, which may reduce the need to proceed to
surgery.26,27 Fukumoto et al26 found in their multicenter
retrospective study that the ileum is the most common location
for strictures and that CD is the underlying cause in most of
these cases. Double balloon endoscopy is helpful in both
diagnosis and treatment of those strictures, with 70% of pa-
tients achieving long-term success.26 Ohmiya et al,27 in their
single tertiary center study of 66 patients with small bowel
obstruction, found similar results: double balloon endoscopy
has a high diagnostic yield of small bowel obstruction and its
cause with 69% of CD patients obtaining long-term relieve.
The remainder experienced relapse of the stricture requiring
either further dilation or ultimately surgery.27
Perforation is relatively rare in CD, only occurring in
1e3% of cases.28 When it occurs, it can affect any part of the
GI tract, such as ileum, jejunum, gastroduodenum, or most
commonly, the colon. When affecting the colon, it is
commonly a complication of toxic colitis or acute active
inflammation in combination with distal obstruction.28 In
cases where perforation is suspected, urgent resuscitation is
necessary prior to emergency abdominal surgery. This in-
cludes adequate fluid replacement and broad-spectrum anti-
biotics, and also additional (stress) steroids, if the patient has
been on steroids prior to admission. Again, close liaison with
the general surgical team on-call is key to success. The general
workup includes a full blood count, urea and electrolytes,
coagulation studies, and cross match. Plain abdominal radio-
graphs with erect chest X-ray are also vital to aid succinct
diagnosis and to look for colonic dilation, or free intraperito-
neal air. It is important, however, to remember that pneumo-
peritoneum is only present in 20% of perforated CD and is
even less common with ileal perforation.28
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In CD, an intra-abdominal mass may be secondary to bowel
distension proximal to a stricture, edematous bowel loops due
to acute inflammation, phlegmon with associated fistulae, or
an abscess cavity. In contrast to a patient with acute perfora-
tion, who presents with free gas in the abdominal cavity, pa-
tients with perforating CD develop walled-off abscesses as a
result of chronic seepage of bacteria and intestinal content
through transluminal sinus tracks. Approximately 25% of
patients with CD will have an abscess at some point in their
life.29,30 Abscesses are mainly either intraperitoneal or retro-
peritoneal, and their location is defined by the location of
active intestinal CD, most commonly in the right lower
quadrant adjacent to the terminal ileum.9
The signs and symptoms of an intra-abdominal abscess are
often difficult to distinguish from a CD flare-up: both clinical
scenarios are characterized by abdominal pain, fever, fatigue,
and raised white cell counts. The acute physician should also
remember that patients receiving steroids (some CD patients
may still be treated with long-term steroids, albeit outdated,
because of more effective and newer biologics) may have a
blunted temperature response to infection, and an abscess in
these patients may therefore easily go undetected. In general,
investigations that aid diagnosis may include plain abdominal
radiographs, abdominal ultrasound, or CT abdomen  pelvis.
Owing to the nonspecific presentation of CD abscesses, some
clinicianswill prefer to perform aCTabdomenwith pelvis at the
point of admission; others may prefer towait for the opinion and
guidance by gastroenterologists. Patients with groin pain or
difficulty with hip flexion must, however, have a CTwith deep
pelvic and groin images to exclude an iliopsoas abscess.30
Management of intra-abdominal abscesses should be mul-
tiprofessional in nature, including physicians and general
surgeons. Initially, broad-spectrum intravenous antibiotics are
administered and the abscess is first drained percutaneously
(under CT or ultrasound guidance), and only if this does not
lead to resolution, will surgery follow in the acute setting.31,32
In general, surgery is not required in the majority of cases, as
supported by a recent United States nationwide study
revealing that only 32% of CD-related intra-abdominal ab-
scesses ultimately proceed to surgery.32 Ananthakrishnan and
McGinley32 reviewed the admission details of 3296 CD pa-
tients with abdominal abscesses and found that approximately
39% were successfully treated by medical treatment alone and
29% were treated by percutaneous drainage never requiring
surgery. Surgery was more likely only in patients with mul-
tiple comorbidities or complicated CD, such as fistulae and
abscesses. Since 1998, the frequency of percutaneous drainage
has increased, now presenting the first choice of therapy for
many CD-related intra-abdominal abscesses.32 Acute physi-
cians will commonly be presented with the dilemma of
treating a combination of active CD with intra-abdominal
abscess33; therefore, the physician must weigh the benefits
of using immunosuppressive therapies for active IBD against
the risks of immunosuppression in the presence of seriousabdominal infection. There is no “one answer fits all”
approach, and seeking the opinion of a gastroenterologist early
on is strongly advised.31
Approximately 30% of patients with CD develop perianal
or perirectal fistulae, and these are commonly associated with
an underlying chronic abscess.34 Besides flatulence and
drainage of pus from a perianal fistula, anal pain and
discomfort (worsened by sitting or defecation) should alert the
acute physician to the presence of an occult perianal abscess.
On examination, there is significant tenderness to palpation
with erythema and induration of the skin overlying the peri-
anal space. As the treatment of perianal CD remains a chal-
lenge to both physicians and surgeons alike, expert advice
should be sought early, for example, by prompt referral to a
gastroenterologist. Surgical input is required for drainage
followed by oral antibiotics to aid closure of the fistula tract.
Ciprofloxacin and metronidazole with both antimicrobial and
fistula-healing properties are preferred.30 Delay in definitive
treatment may lead to overwhelming sepsis, sphincter
impairment, or anal stenosis.9
The acute physician should also be aware of the potential of
malignant transformation of a fistulous tract in CD, albeit rare.
The fistula most commonly originates in the rectum and is of
adenocarcinoma type. Diagnosis is difficult and often delayed
owing to a lack of and specificity of symptoms and signs. Only
if the physician has a high level of suspicion, especially if
fistulous drainage persists or is refractory to medical therapy,
may the diagnosis be made early on. In case of doubt, repeat
biopsies from the fistula and surrounding structures/tissue may
guide management.35
6. Hepatobiliary disease
Approximately 3e7.5% of all IBD patients have associated
hepatobilliary disease. In general, hepatobiliary manifestations
are more common in ulcerative colitis than in CD patients.35
Primary sclerosing cholangitis (and not primary biliary
cirrhosis) is the most clinically significant hepatobilliary dis-
ease associated with ulcerative colitis, whereas gallstones,
cholangitis, and pancreatitis are more common in CD
patients.30,36e39 Cholelithiasis is common in patients with CD,
especially with terminal ileum involvement. The presence of
ileal involvement in CD or ileal resection can lead to a
disruption of the reabsorption of bile salts in the terminal
ileum and cholesterol-supersaturated bile. In addition, patients
with CD have reduced gallbladder motility.37 Acute pancrea-
titis associated with CD may be related to gallstones, disease
of the duodenum with papillary injury, or CD-associated
granulomatous inflammation of the pancreas. The acute
physician should remember that an elevation of serum amylase
is not necessarily indicative of acute pancreatitis. Navaneethan
et al37 described that abnormal serum level of amylase was
shown in only 5.8e15.8% of patients with CD, and therefore,
a high level of suspicion is necessary for diagnosis. Chronic
pancreatitis appears to be more common in CD than ulcerative
colitis patients and appears to be predominantly asymptom-
atic. Although only 2% of CD patients have clinically
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that histological pancreatitis is present in up to 53% of cases
with 80% having pancreatic exocrine insufficiency.37
With regard to recent advances in therapy of CD (and also
ulcerative colitis), the acute physician also needs to consider
diseases related to adverse effects associated with treatment,
including drug-induced hepatitis, pancreatitis (purine-based
agents), or liver cirrhosis (methotrexate), and reactivation of
hepatitis B, and biologic agent-associated hepatosplenic lym-
phoma.37 Patients on 6-mercaptopurine or azathioprine or
methotrexate require periodic monitoring of liver function
tests (LFTs) every 1e3 months, and patients on biologics
require monitoring of LFTs at least every 3e6 months. Pa-
tients with abnormal LFTs should then have their medication
discontinued. When patients with CD flare-ups are admitted to
the AMU, it is the responsibility of the admitting physician to
review blood results and to act accordingly or ask a gastro-
enterologist for prompt advice. Initial screens for the presence
of hepatitis B infection should also have been performed in all
patients on biologics, with hepatitis B surface antigen, anti-
hepatitis B, and anti-hepatitis B core antibody, and a good
acute physician should at least review or even repeat the
hepatitis screen when clinically indicated in CD patients with
deranged LFTs.
7. Venous thromboembolism
Multiple large studies have demonstrated that CD (and also
ulcerative colitis) patients have a 1.5e3.5-fold higher risk of
incurring VTEs when compared with non-IBD patients. IBD
activity is associated with the development of VTEs, and, in
general, disease activity has emerged as an independent risk
factor of VTE development. Although the greatest relative
increase in the risk of VTEs with disease activity was observed
in ambulatory patients, hospitalized IBD patients had a
markedly higher baseline risk of VTEs than ambulatory pa-
tients. Among VTE-related hospitalizations, the presence of
IBD was associated with a 2.5-fold increased risk of mortal-
ity.40 The latter finding was also supported by Nguyen and
Sam,41 who found that age- and comorbidity-adjusted excess
mortality from VTE was 2.1-fold higher for IBD than for non-
IBD patients. They also found that among CD patients, active
fistulizing disease was independently associated with greater
VTE risk.41 Recent research seems to suggest, however, that
the incidence of VTE among medical patients with CD is less
than those with ulcerative colitis.42
The cause of a state of hypercoagulability is unclear, but
appears to be related to coagulation imbalances, such as
increased levels of plasminogen activator inhibitor, coagula-
tion factors V and VIII, and fibrinogen and decreased levels of
factor V Leiden, antithrombin III, and protein C and S.30
Approximately 65% of VTE events in patients with CD
manifested as lower extremity deep vein thrombosis and pul-
monary embolus. VTE events affecting mesenteric, peripheral
vessels, portal and hepatic veins, cardiac blood vessels, cere-
bral veins, gonadal veins, and retinal vessels have all been
reported, but are very rare.30Once a clinical diagnosis of VTE has been made, anti-
coagulation is required. Although anticoagulation with heparin
seems counterproductive in a patient with actively bleeding
CD, studies to date do not support an increased bleeding risk
with moderate doses of anticoagulant medications.40 Patients
with recurrent pulmonary emboli from thrombosis of the
ileofemoral veins and massive colonic bleeding during anti-
coagulation require vena cava filter placement with or without
colectomy.30
To date, there have been no studies objectively evaluating
the use of prophylactic anticoagulation in patients with active
CD, either ambulatory or hospitalized.
8. Intestinal failure
Acute intestinal failure in CD can occur in a variety of
clinical settings, including extensive jejunoileitis, a high
jejunocutaneous or jejunocolonic fistula, or following exten-
sive small bowel resection. Although this presentation is not
common, it is important to recognize and treat promptly
because it leads to metabolic imbalances, such as severe
dehydration and electrolyte imbalance, hypoalbuminemia, and
rapid weight loss. The most challenging problem for the acute
physician is the prompt and adequate fluid and electrolyte
replacement.7 In acute intestinal failure, the intestinal fluid
loss can be in excess of 5 L per 24 hours and resemble
secretory diarrhea. Failure to absorb fluid and electrolytes,
especially sodium and magnesium, results in the most clini-
cally important deficit in the acute phase. Initially, it is
appropriate to give intravenous normal saline to rehydrate the
patient and to replenish the body’s sodium levels. Magnesium
may also have to be replaced intravenously. Generally, po-
tassium deficiency is uncommon in intestinal failure and only
seen when there is less than 50 cm of the residual small in-
testine.7 For acute physicians, it is of paramount importance to
realize when level one care on AMU may no longer be
appropriate and to refer to intensivists early to optimize fluid
and electrolyte balance.
Diagnosis is based on conventional small bowel radiology,
such as barium follow through or enteroclysis, colonoscopy,
and small intestinal biopsy (to exclude gluten-sensitive en-
teropathy). Following initial resuscitation, treatment is best
delivered in a structured and multidisciplinary approach with
gastroenterologists and dieticians at the center. The first step is
to exclude underlying sepsis, as sepsis will have to have
resolved, prior to achieving adequate nutritional repletion.43
This will often be the main role of the acute physician on
AMU prior to the patients receiving specialist care on
gastroenterology wards. In cases where underlying fistulae are
a concern, acute physicians may also refer the patient for
surgical opinion.
9. Conclusion
When assessing patients with vague abdominal symptoms,
acute physicians should consider a first presentation of CD as
part of their differential diagnosis. Toxic colitis and
137V.N. Go¨tz / Journal of Acute Medicine 3 (2013) 132e137megacolon are easy to spot, but are at the extreme end of the
spectrum of presenting symptoms. To consider a diagnosis of
CD in patients with per rectum bleeding, deranged LFTs or
those with VTE’s may be more challenging. In any case,
diagnosis depends on the vigilance of the acute physician and
often relies on good initial resuscitation and stabilization of
the patient with early involvement of the gastroenterologist in
combination with general surgeons.
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